Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Solventum CorporationNYSE: SOLV
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings rises 306.4% from a year ago
Retained earnings stood at $1.9B at the end of Q2 FY2026, up 306.4% from a year earlier and up 5.1% from the prior quarter.
Context
- Retained earnings amounted to 13.4% of total assets at the end of Q2 FY2026, up 10.2 pp from a year earlier.
- Retained earnings increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +306.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- 1.8B USD
- Year-over-year change
- +642.6%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.8B | +642.6% |
| FY2024 | 2024-12-31 | 242M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Retained Earnings vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's Jun 2026 retained earnings of $1.9B is the 4th highest of the 10 companies compared; the peer median is $740.11M.
- Its year-over-year change of +306.4% is the highest of 10, against a peer median of +1.6%.
- Retained earnings amounts to 13.4% of total assets for SOLV, versus a peer median of 29.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $13.81B | -7.8% | -0.8% | 69.8% | |
| Jul 2026 | $8.13B | +7.5% | +5.1% | 64.1% | |
| Jun 2026 | $3.2B | -8.2% | -3.6% | 28.1% | |
| Jun 2026 | $1.9B | +306.4% | — | 13.4% | |
| Sep 2026 | $946.14M | +20.4% | +19.7% | — | |
| Jun 2026 | $740.11M | +4.2% | -6.2% | 18.6% | |
| Oct 2026 | $160.3M | +133.9% | — | 2.9% | |
| Mar 2026 | $130.26M | +1.6% | +0.7% | 104.7% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | -$1.57B | -85.6% | — | 30.1% | |
| Peer median (excluding SOLV) | $740.11M | +1.6% | -0.1% | 29.1% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 91M | 61M | 194M | 762M | 878M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.18B | 1.17B | 1.31B | 1.23B | 1.03B |
| Inventory | 813M | 873M | 857M | 965M | 1.07B |
| Other Current Assets | 108M | 126M | 155M | 293M | 881M |
| Total Current Assets | 2.19B | 2.23B | 2.52B | 3.25B | 3.86B |
| Property, Plant & Equipment (Net) | 1.31B | 1.32B | 1.46B | 1.62B | 1.33B |
| Goodwill | 6.67B | 6.43B | 6.54B | 6.38B | 5.7B |
| Intangible Assets | 3.66B | 3.25B | 2.9B | 2.54B | 2.59B |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 253M | 358M | 530M | 665M | 813M |
| Total Non-current Assets | 11.89B | 11.36B | 11.42B | 11.21B | 10.44B |
| Total Assets | 14.08B | 13.59B | 13.94B | 14.46B | 14.29B |
| Account Payables | 320M | 348M | 477M | 618M | 687M |
| Short-term Debt | 0 | 27M | 0 | 200M | 0 |
| Tax Payables | 0 | 0 | 106M | 122M | 0 |
| Deferred Revenue | 0 | 559M | 574M | 572M | 621M |
| Other Current Liabilities | 732M | 312M | 365M | 659M | 1.83B |
| Total Current Liabilities | 1.41B | 1.31B | 1.73B | 2.7B | 3.14B |
| Long-term Debt | 0 | 0 | 8.3B | 7.81B | 5.04B |
| Deferred Tax Liabilities | 0 | 215M | 231M | 225M | 164M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 527M | 258M | (7.99B) | 760M | 910M |
| Total Non-current Liabilities | 610M | 541M | 549M | 8.8B | 6.11B |
| Total Liabilities | 2.02B | 1.85B | 2.28B | 11.5B | 9.25B |
| Common Stock | 0 | 0 | 0 | 2M | 2M |
| Retained Earnings | 0 | 0 | 0 | 242M | 1.8B |
| Accumulated OCI | (200M) | (497M) | (337M) | (1.06B) | (625M) |
| Other Stockholders Equity | 12.26B | 12.24B | 12B | 0 | 3.88B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 12.06B | 11.74B | 11.67B | 2.96B | 5.05B |
| Total Debt | 112M | 95M | 8.3B | 8.01B | 5.04B |
| Net Debt | 21M | 34M | 8.11B | 7.25B | 4.16B |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.